Results 181 to 190 of about 334,749 (357)

Cancer vaccines [PDF]

European Journal of Cancer, 1994
openaire   +3 more sources

Engaging the Immune Response to Normalize the Tumor Microenvironment [PDF]

, 2013
Solid tumors exist as heterogeneous populations comprised not only of malignant cells, but various other cell types, including cells that make up the vasculature, that can strongly influence tumorgenicity.
Sabins, Nina, Storkus, Walter
core  

Targeting Antigen‐Presenting Cells to Enhance the Tumor‐Spleen Immunity Cycle through Liposome‐Neoantigen Vaccine

Advanced Science, EarlyView.
LNPsD18, a cationic liposome that enhances antigen‐presenting cell uptake in the spleen and tumor without targeting ligands is developed. Co‐delivering neoantigens and a TLR9 agonist significantly improve DC activation, tumor immunity, and survival in liver and colorectal cancer models, demonstrating the importance of dual‐site APC targeting for cancer
Yu Xu, Bing Wang, Yue Huang, JianPing Liao, Chenyi Wu, Chenxi Zhou, Zishi Kang, Shiyang Jiang, Bing‐Chen Wu, Da Zhang, Ruihua Xu, Xiaolong Liu, Feng Wang   +12 more
wiley   +1 more source

Antitumor efficacy of tumor-antigen-encoding recombinant poxvirus immunization in Dunning rat prostate cancer: implications for clinical genetic vaccine development [PDF]

, 2000
Linda G. Charles, Yilin C. Xie, Nicholas P. Restifo, Blake J. Roessler, Martin G. Sanda   +4 more
openalex   +1 more source

KK2DP7 Stimulates CD11b+ Cell Populations in the Spleen to Elicit Trained Immunity for Anti‐Tumor Therapy

Advanced Science, EarlyView.
This study introduces KK2DP7, a dendrimer‐structured peptide adjuvant, as a tool to decode trained immunity's role in antitumor therapy. Splenic CD11b+ cells mediate tumor suppression via TLR2‐IRF7 activation and epigenetic reprogramming, validated by adoptive transfer experiments.
Rui Zhang, Lin Tang, Yusi Wang, Xuejing Zhou, Zhenyu Ding, Li Yang   +5 more
wiley   +1 more source

Current updates of CRISPR/Cas9‐mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management

Cancer Communications, Volume 42, Issue 12, Page 1257-1287, December 2022., 2022
Abstract Clustered regularly interspaced short palindromic repeats‐associated protein (CRISPR/Cas9), an adaptive microbial immune system, has been exploited as a robust, accurate, efficient and programmable method for genome targeting and editing. This innovative and revolutionary technique can play a significant role in animal modeling, in vivo genome
Khaled S. Allemailem, Mohammed A Alsahli, Ahmad Almatroudi, Faris Alrumaihi, Fahd Khaleefah Alkhaleefah, Arshad Husain Rahmani, Amjad Ali Khan   +6 more
wiley   +1 more source

Engineered Genetic Circuits Activated by Bezafibrate Improve ESC‐Based TAA Cancer Vaccine Efficacy and PD‐L1 Nanobody Therapy

Advanced Science, EarlyView.
Synthetic gene circuits regulated by bezafibrate are developed to express tumor antigens and PD‐L1 nanobody (PD‐L1nb), enhancing cancer immunotherapy. Delivered via HEK293T cells, ESCs, or directly injected the plasmids containing the circuit into the tumor, the circuits reduce tumor growth, boost CD8+ T cells, and minimize T cell exhaustion.
Meiling Jin, Shuzhen Liu, Mingshuo Zhan, Jian‐Dong Huang   +3 more
wiley   +1 more source

Gene-modified spontaneous Epstein-Barr virus-transformed lymphoblastoid cell lines as autologous cancer vaccines: Mutated p21 ras oncogene as a model [PDF]

, 2000
Boris Kubuschok, Christiane Cochlovius, Wolfram Jung, Rudolf Schmits, Lorenz Trümper, Frank Hartmann, Christoph Renner, Michael Pfreundschuh   +7 more
openalex   +1 more source

Sortilin‐Mediated Rapid, Precise and Sustained Degradation of Membrane Proteins via mRNA‐Encoded Lysosome‐Targeting Chimera

Advanced Science, EarlyView.
The study identified sortilin as a promising LTR, enabling targeted degradation of oncogenic proteins through an mRNA‐encoded MedTAC strategy. In a mouse model, MedTACPTK7 reduced PTK7 by up to 80%, extended survival, and showed excellent pharmacokinetics without toxicity, providing a scalable platform for targeted therapies.
Xin Chang, Xinyu Qiu, Xiaoning Tong, Shaoju Gan, Weicheng Yi, Sitao Xie, Xiangsheng Liu, Chao Zuo, Weihong Tan   +8 more
wiley   +1 more source

Novel Bivalent mRNA‐LNP Vaccine for Highly Effective Protection against Pneumonic Plague

Advanced Science, EarlyView.
The study investigates mRNA‐lipid nanoparticle vaccines targeting Yersinia pestis, the causative agent of plague. Combined F1+LcrV mRNA vaccination elicited robust immune responses and protected mice against virulent wild‐type and atypical strains.
Uri Elia, Yinon Levy, Hila Cohen, Ayelet Zauberman, David Gur, Inbal Hazan‐Halevy, Moshe Aftalion, Shani Benarroch, Erez Bar‐Haim, Orit Redy‐Keisar, Ofer Cohen, Dan Peer, Emanuelle Mamroud   +12 more
wiley   +1 more source